- Home
- JELD vs VRXA Comparison
JELD vs VRXA Comparison
Compare JELD & VRXA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JELD | VRXA |
|---|---|---|
| Founded | 1960 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.7M | 161.2M |
| IPO Year | 2016 | 2025 |
Fundamental Metrics
Financial Performance| Metric | JELD | VRXA |
|---|---|---|
| Price | $1.04 | $0.95 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $1.93 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 260.0K |
| Earning Date | 11-03-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,211,181,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.93 | $0.95 |
| 52 Week High | $3.27 | $4.50 |
Technical Indicators
Market Signals| Indicator | JELD | VRXA |
|---|---|---|
| Relative Strength Index (RSI) | 31.30 | 36.66 |
| Support Level | $0.93 | N/A |
| Resistance Level | $1.47 | $1.25 |
| Average True Range (ATR) | 0.14 | 0.10 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 19.24 | 9.06 |
Price Performance
Historical ComparisonAbout JELD JELD-WEN Holding Inc.
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.
About VRXA Veraxa Biotech AG Ordinary Shares
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.